

# Fabrizio Tediosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1759410/publications.pdf>

Version: 2024-02-01

124  
papers

5,083  
citations

147801

31  
h-index

102487

66  
g-index

134  
all docs

134  
docs citations

134  
times ranked

9178  
citing authors

#	ARTICLE	IF	CITATIONS
1	Community perceptions of enrolment of indigents into the National Health Insurance Scheme in Ghana: a case study of the Livelihood Empowerment against Poverty Programme. <i>Global Health Research and Policy</i> , 2022, 7, 4.	3.6	3
2	Equity in health insurance schemes enrollment in low and middle-income countries: A systematic review and meta-analysis. <i>International Journal for Equity in Health</i> , 2022, 21, 21.	3.5	27
3	Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo. <i>Nature Communications</i> , 2022, 13, 1051.	12.8	7
4	Testing the contextual Interaction theory in a UHC pilot district in South Africa. <i>BMC Health Services Research</i> , 2022, 22, 343.	2.2	0
5	Burden of Covid-19 restrictions: National, regional and global estimates. <i>EClinicalMedicine</i> , 2022, 45, 101305.	7.1	23
6	Health insurance coverage in low-income and middle-income countries: progress made to date and related changes in private and public health expenditure. <i>BMJ Global Health</i> , 2022, 7, e008722.	4.7	23
7	How to bring research evidence into policy? Synthesizing strategies of five research projects in low-and middle-income countries. <i>Health Research Policy and Systems</i> , 2021, 19, 29.	2.8	18
8	How does it affect service delivery under the National Health Insurance Scheme in Ghana? Health providers and insurance managers perspective on submission and reimbursement of claims. <i>PLoS ONE</i> , 2021, 16, e0247397.	2.5	12
9	Insured clients out-of-pocket payments for health care under the national health insurance scheme in Ghana. <i>BMC Health Services Research</i> , 2021, 21, 440.	2.2	20
10	A Complexity Lens on the COVID-19 Pandemic. <i>International Journal of Health Policy and Management</i> , 2021, , .	0.9	14
11	Effect of specificity of health expenditure questions in the measurement of out-of-pocket health expenditure: evidence from field experimental study in Ghana. <i>BMJ Open</i> , 2021, 11, e042562.	1.9	1
12	Positioning the National Health Insurance for financial sustainability and Universal Health Coverage in Ghana: A qualitative study among key stakeholders. <i>PLoS ONE</i> , 2021, 16, e0253109.	2.5	16
13	Costing interventions in the field: preliminary cost estimates and lessons learned from an evaluation of community-wide mass drug administration for elimination of soil-transmitted helminths in the DeWorm3 trial. <i>BMJ Open</i> , 2021, 11, e049734.	1.9	2
14	Building a multisystemic understanding of societal resilience to the COVID-19 pandemic. <i>BMJ Global Health</i> , 2021, 6, e006794.	4.7	20
15	A health systems resilience research agenda: moving from concept to practice. <i>BMJ Global Health</i> , 2021, 6, e006779.	4.7	51
16	Governance factors that affect the implementation of health financing reforms in Tanzania: an exploratory study of stakeholdersâ€™ perspectives. <i>BMJ Global Health</i> , 2021, 6, e005964.	4.7	12
17	Challenges and experiences in linking community level reported out-of-pocket health expenditures to health provider recorded health expenditures: Experience from the iHOPE project in Northern Ghana. <i>PLoS ONE</i> , 2021, 16, e0256910.	2.5	2
18	Impact of social accountability monitoring on health facility performance: Evidence from Tanzania. <i>Health Economics (United Kingdom)</i> , 2021, 30, 766-785.	1.7	5

#	ARTICLE	IF	CITATIONS
19	A network analysis of patient referrals in two district health systems in Tanzania. <i>Health Policy and Planning</i> , 2021, 36, 162-175.	2.7	2
20	Economic evaluation of disease elimination: An extension to the net-benefit framework and application to human African trypanosomiasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	3
21	Build back stronger universal health coverage systems after the COVID-19 pandemic: the need for better governance and linkage with universal social protection. <i>BMJ Global Health</i> , 2020, 5, e004020.	4.7	32
22	The roles of a Grandmother in African societies “ please do not send them to old people’s homes. <i>Journal of Global Health</i> , 2020, 10, 010361.	2.7	5
23	Cost and cost drivers associated with setting-up a prime vendor system to complement the national medicines supply chain in Tanzania. <i>BMJ Global Health</i> , 2020, 5, e002681.	4.7	1
24	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	13.7	330
25	Estimated need for anthelmintic medicines to control soil-transmitted helminthiasis in school-aged children, 2020–2030. <i>Infectious Diseases of Poverty</i> , 2020, 9, 48.	3.7	4
26	The effects of medicines availability and stock-outs on household’s utilization of healthcare services in Dodoma region, Tanzania. <i>Health Policy and Planning</i> , 2020, 35, 323-333.	2.7	30
27	The role of accountability in the performance of Jazia prime vendor system in Tanzania. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 25.	2.4	10
28	Cost of interventions to control schistosomiasis: A systematic review of the literature. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008098.	3.0	18
29	Health systems and global progress towards malaria elimination, 2000–2016. <i>Malaria Journal</i> , 2020, 19, 141.	2.3	12
30	Acceptability of a Prime Vendor System in Public Healthcare Facilities in Tanzania. <i>International Journal of Health Policy and Management</i> , 2020, 10, 625-637.	0.9	4
31	SCORE Operational Research on Moving toward Interruption of Schistosomiasis Transmission. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 58-65.	1.4	21
32	Financial Costs of the Zanzibar Elimination of Schistosomiasis Transmission Project. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2260-2267.	1.4	3
33	What we need is health system transformation and not health system strengthening for universal health coverage to work: Perspectives from a National Health Insurance pilot site in South Africa. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2020, 62, e1-e15.	0.6	8
34	Investigating the effect of recall period on estimates of inpatient out-of-pocket expenditure from household surveys in Vietnam. <i>PLoS ONE</i> , 2020, 15, e0242734.	2.5	2
35	The roles of a Grandmother in African societies “ please do not send them to old people’s homes. <i>Journal of Global Health</i> , 2019, 9, 010306.	2.7	11
36	Sociodemographic determinants of health insurance enrolment and dropout in urban district of Ghana: a cross-sectional study. <i>Health Economics Review</i> , 2019, 9, 23.	2.0	25

#	ARTICLE	IF	CITATIONS
37	VIBRA trial – Effect of village-based refill of ART following home-based same-day ART initiation vs clinic-based ART refill on viral suppression among individuals living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho. <i>Trials</i> , 2019, 20, 522.	1.6	9
38	The challenge of ensuring equity in mass deworming programmes. <i>The Lancet Global Health</i> , 2019, 7, e1468-e1469.	6.3	0
39	Determinants of health insurance enrolment in Ghana: evidence from three national household surveys. <i>Health Policy and Planning</i> , 2019, 34, 582-594.	2.7	36
40	Inequalities in the benefits of national health insurance on financial protection from out-of-pocket payments and access to health services: cross-sectional evidence from Ghana. <i>Health Policy and Planning</i> , 2019, 34, 694-705.	2.7	38
41	Looking at the bigger picture: how the wider health financing context affects the implementation of the Tanzanian Community Health Funds. <i>Health Policy and Planning</i> , 2019, 34, 12-23.	2.7	18
42	Is the elimination of –sleeping sickness– affordable? Who will pay the price? Assessing the financial burden for the elimination of human African trypanosomiasis <i>Trypanosoma brucei gambiense</i> in sub-Saharan Africa. <i>BMJ Global Health</i> , 2019, 4, e001173.	4.7	14
43	Going operational with health systems governance: supervision and incentives to health workers for increased quality of care in Tanzania. <i>Health Policy and Planning</i> , 2019, 34, ii77-ii92.	2.7	8
44	Socio-demographic determinants of low birth weight: Evidence from the Kassena-Nankana districts of the Upper East Region of Ghana. <i>PLoS ONE</i> , 2018, 13, e0206207.	2.5	31
45	Towards improved health service quality in Tanzania: An approach to increase efficiency and effectiveness of routine supportive supervision. <i>PLoS ONE</i> , 2018, 13, e0202735.	2.5	14
46	Ethical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for <i>Trypanosoma brucei gambiense</i> . <i>Public Health Ethics</i> , 2018, 11, 275-292.	1.0	5
47	Evaluating the sustainability, scalability, and replicability of an STH transmission interruption intervention: The DeWorm3 implementation science protocol. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0005988.	3.0	29
48	Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006250.	3.0	29
49	Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet</i> , 2017, 389, 1981-2004.	13.7	204
50	Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa. <i>Vaccine</i> , 2017, 35, 53-60.	3.8	17
51	Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of <i>Trypanosoma brucei gambiense</i> . <i>The Lancet Global Health</i> , 2017, 5, e69-e79.	6.3	47
52	Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. <i>Health Policy</i> , 2017, 121, 745-754.	3.0	33
53	Modelling the health and economic impacts of the elimination of river blindness (onchocerciasis) in Africa. <i>BMJ Global Health</i> , 2017, 2, e000158.	4.7	15
54	The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005289.	3.0	39

#	ARTICLE	IF	CITATIONS
55	Global health policy and neglected tropical diseases: Then, now, and in the years to come. PLoS Neglected Tropical Diseases, 2017, 11, e0005759.	3.0	19
56	How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis. PLoS Neglected Tropical Diseases, 2017, 11, e0005934.	3.0	8
57	Malaria Control. , 2017, , 347-364.		1
58	Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis. Advances in Parasitology, 2016, 94, 393-417.	3.2	5
59	Evidence for optimal allocation of malaria interventions in Africa. The Lancet Global Health, 2016, 4, e432-e433.	6.3	2
60	Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. BMJ Global Health, 2016, 1, e000021.	4.7	19
61	BRICS countries and the global movement for universal health coverage. Health Policy and Planning, 2016, 31, 717-728.	2.7	23
62	European Regional Differences in All-cause Mortality and Length of Stay for Patients with Hip Fracture. Health Economics (United Kingdom), 2015, 24, 53-64.	1.7	51
63	Contemporary and emerging strategies for eliminating human African trypanosomiasis due to <i>Trypanosoma brucei gambiense</i> : review. Tropical Medicine and International Health, 2015, 20, 707-718.	2.3	50
64	Investing in Justice: Ethics, Evidence, and the Eradication Investment Cases for Lymphatic Filariasis and Onchocerciasis. American Journal of Public Health, 2015, 105, 629-636.	2.7	32
65	Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa. PLoS Neglected Tropical Diseases, 2015, 9, e0004056.	3.0	20
66	What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs. PLoS Neglected Tropical Diseases, 2015, 9, e0004147.	3.0	28
67	Mortality and Length of Stay of Very Low Birth Weight and Very Preterm Infants: A EuroHOPE Study. PLoS ONE, 2015, 10, e0131685.	2.5	32
68	Human African trypanosomiasis prevention, treatment and control costs: A systematic review. Acta Tropica, 2015, 150, 4-13.	2.0	54
69	Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data. Vaccine, 2015, 33, 6710-6718.	3.8	20
70	Control, Elimination, and Eradication of River Blindness: Scenarios, Timelines, and Ivermectin Treatment Needs in Africa. PLoS Neglected Tropical Diseases, 2015, 9, e0003664.	3.0	77
71	A Literature Review of Economic Evaluations for a Neglected Tropical Disease: Human African Trypanosomiasis (‘‘Sleeping Sickness’’). PLoS Neglected Tropical Diseases, 2015, 9, e0003397.	3.0	41
72	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544

#	ARTICLE	IF	CITATIONS
73	Effective Coverage and Systems Effectiveness for Malaria Case Management in Sub-Saharan African Countries. PLoS ONE, 2015, 10, e0127818.	2.5	114
74	Can Economic Analysis Contribute to Disease Elimination and Eradication? A Systematic Review. PLoS ONE, 2015, 10, e0130603.	2.5	19
75	BRICS™ role in global health and the promotion of universal health coverage: the debate continues. Bulletin of the World Health Organization, 2014, 92, 452-453.	3.3	14
76	Inputs for universal health coverage: a methodological contribution to finding proxy indicators for financial hardship due to health expenditure. BMC Health Services Research, 2014, 14, 577.	2.2	11
77	Reforming the World Health Organization: what influence do the BRICS wield?. Contemporary Politics, 2014, 20, 163-181.	2.0	15
78	Italy's contribution to global health: the need for a paradigm shift. Globalization and Health, 2014, 10, 25.	4.9	4
79	Intergovernmental relations and Long Term Care reforms: Lessons from the Italian case. Health Policy, 2014, 116, 61-70.	3.0	11
80	Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: A systematic review. Acta Tropica, 2014, 135, 86-95.	2.0	42
81	“BRICS without straw”? A systematic literature review of newly emerging economies' influence in global health. Globalization and Health, 2013, 9, 15.	4.9	36
82	Beyond antimalarial stock-outs: implications of health provider compliance on out-of-pocket expenditure during care-seeking for fever in South East Tanzania. BMC Health Services Research, 2013, 13, 444.	2.2	27
83	Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine, 2013, 31, 380-386.	3.8	17
84	The Importance of Values in Shaping How Health Systems Governance and Management Can Support Universal Health Coverage. Value in Health, 2013, 16, S19-S23.	0.3	22
85	Developing Eradication Investment Cases for Onchocerciasis, Lymphatic Filariasis, and Human African Trypanosomiasis: Rationale and Main Challenges. PLoS Neglected Tropical Diseases, 2013, 7, e2446.	3.0	21
86	The policy of free healthcare for children under the age of 6 years in Vietnam: assessment of the uptake for children hospitalised with acute diarrhoea in Ho Chi Minh City. Tropical Medicine and International Health, 2013, 18, 1444-1451.	2.3	3
87	Simulating the impact of malaria vaccination: what has been learnt?. Expert Review of Vaccines, 2012, 11, 751-753.	4.4	0
88	IMPLEMENTING PERFORMANCE-BASED FUNDING FOR HEALTH RESEARCH: WHEN GOVERNANCE AND PROCEDURAL FAIRNESS MATTER. Public Administration, 2012, 90, 313-334.	3.5	9
89	Cost-Effectiveness of the Introduction of a Pre-Erythrocytic Malaria Vaccine into the Expanded Program on Immunization in Sub-Saharan Africa: Analysis of Uncertainties Using a Stochastic Individual-Based Simulation Model of Plasmodium falciparum Malaria. Value in Health, 2011, 14, 1028-1038.	0.3	26
90	Cost-effectiveness of intermittent preventive treatment of malaria in infants (IPTi) for averting anaemia in Gabon: a comparison between intention to treat and according to protocol analyses. Malaria Journal, 2011, 10, 305.	2.3	3

#	ARTICLE	IF	CITATIONS
91	Cost Implications of Improving Malaria Diagnosis: Findings from North-Eastern Tanzania. PLoS ONE, 2010, 5, e8707.	2.5	36
92	The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub-Saharan Africa. PLoS ONE, 2010, 5, e10313.	2.5	38
93	Governing decentralization in health care under tough budget constraint: What can we learn from the Italian experience?. Health Policy, 2009, 90, 303-312.	3.0	90
94	Simplifying paediatric immunization with a fully liquid DTPa+HepB+Hib combination vaccine: Evidence from a comparative time-motion study in India. Vaccine, 2009, 27, 655-659.	3.8	28
95	Simulation of the cost-effectiveness of malaria vaccines. Malaria Journal, 2009, 8, 127.	2.3	31
96	Costs and cost-effectiveness of vector control in Eritrea using insecticide-treated bed nets. Malaria Journal, 2009, 8, 51.	2.3	31
97	G8 Summit 2009: what approach will Italy take to health?. Lancet, The, 2009, 374, 9-10.	13.7	5
98	Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bulletin of the World Health Organization, 2009, 87, 123-129.	3.3	38
99	Access to medicines and out of pocket payments for primary care: Evidence from family medicine users in rural Tajikistan. BMC Health Services Research, 2008, 8, 109.	2.2	25
100	Costs and consequences of large-scale vector control for malaria. Malaria Journal, 2008, 7, 258.	2.3	115
101	Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology, 2008, 135, 1507-1516.	1.5	105
102	Evaluation of the costs and benefits of interventions to reduce indoor air pollution. Energy for Sustainable Development, 2007, 11, 34-43.	4.5	58
103	The impact of different rehabilitation strategies after major events in the elderly: the case of stroke and hip fracture in the Tuscany region. BMC Health Services Research, 2007, 7, 95.	2.2	15
104	PREDICTIONS OF THE EPIDEMIOLOGIC IMPACT OF INTRODUCING A PRE-ERYTHROCYTIC VACCINE INTO THE EXPANDED PROGRAM ON IMMUNIZATION IN SUB-SAHARAN AFRICA. American Journal of Tropical Medicine and Hygiene, 2006, 75, 111-118.	1.4	49
105	THE COSTS OF INTRODUCING A MALARIA VACCINE THROUGH THE EXPANDED PROGRAM ON IMMUNIZATION IN TANZANIA. American Journal of Tropical Medicine and Hygiene, 2006, 75, 119-130.	1.4	35
106	PREDICTING THE COST-EFFECTIVENESS OF INTRODUCING A PRE-ERYTHROCYTIC MALARIA VACCINE INTO THE EXPANDED PROGRAM ON IMMUNIZATION IN TANZANIA. American Journal of Tropical Medicine and Hygiene, 2006, 75, 131-143.	1.4	31
107	MATHEMATICAL MODELING OF THE IMPACT OF MALARIA VACCINES ON THE CLINICAL EPIDEMIOLOGY AND NATURAL HISTORY OF PLASMODIUM FALCIPARUM MALARIA: OVERVIEW. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1-10.	1.4	148
108	AN APPROACH TO MODEL THE COSTS AND EFFECTS OF CASE MANAGEMENT OF PLASMODIUM FALCIPARUM MALARIA IN SUB-SAHARAN AFRICA. American Journal of Tropical Medicine and Hygiene, 2006, 75, 90-103.	1.4	55

#	ARTICLE	IF	CITATIONS
109	Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. <i>Pharmacoeconomics Italian Research Articles</i> , 2002, 4, 81-89.	0.2	4
110	Pharmacoeconomic analysis of prescriptions in Italian pediatric general practice. <i>European Journal of Health Economics</i> , 2002, 3, 261-266.	2.8	2
111	A comparative analysis of domiciliary oxygen therapy in five European countries. <i>Health Policy</i> , 2001, 58, 133-149.	3.0	7
112	Direct Costs of Schizophrenia in Italian Community Psychiatric Services. <i>Pharmacoeconomics</i> , 2001, 19, 1217-1225.	3.3	19
113	Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2001, 13, 733-741.	1.2	34
114	Cost Analysis of Dialysis Modalities in Italy. <i>Health Services Management Research</i> , 2001, 14, 9-17.	1.7	15
115	The Outpatient Cost of Diabetes Care in Italian Diabetes Centers. <i>Value in Health</i> , 2001, 4, 251-257.	0.3	19
116	The Costs of Childhood Epilepsy in Italy: Comparative Findings from Three Health Care Settings. <i>Epilepsia</i> , 2001, 42, 641-646.	5.1	38
117	Cost analysis of dialysis modalities in Italy. <i>Health Services Management Research</i> , 2001, 14, 9-17.	1.7	11
118	How Do Italian Pharmacoeconomists Evaluate Indirect Costs?. <i>Value in Health</i> , 2000, 3, 270-276.	0.3	12
119	Cost of schizophrenia studies: a methodological review. <i>European Journal of Health Economics</i> , 2000, 1, 14-19.	0.2	5
120	A comparative analysis of generics markets in five European countries. <i>Health Policy</i> , 2000, 51, 149-162.	3.0	109
121	The Cost of Urinary Incontinence in Italian Women. <i>Pharmacoeconomics</i> , 2000, 17, 71-76.	3.3	19
122	Costs of Diabetes. <i>Pharmacoeconomics</i> , 1999, 15, 583-595.	3.3	48
123	Universal health coverage financing in South Africa: wishes vs reality. <i>Journal of Global Health Reports</i> , 0, 4, .	1.0	7
124	Lest we forget, primary health care in Sub-Saharan Africa is nurse led. Is this reflected in the current health systems strengthening undertakings and initiatives?. <i>Journal of Global Health Reports</i> , 0, 2, .	1.0	3